The Application of Clinical Genetics Dovepress Splicing Modulation Therapy in the Treatment of Genetic Diseases

No abstract is available for this paper.

• Publication year

  year unknown

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Eteplirsen in the treatment of Duchenne muscular dystrophy

  2017cited by this paper
• Dystrophin Analysis in Clinical Trials

  2014cited by this paper
• Translational and Regulatory Challenges for Exon Skipping Therapies

  2014cited by this paper
• Antisense-Mediated Exon Skipping: Networking to Meet Opportunities and to Overcome Challenges

  2014cited by this paper
• Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials.

  2014cited by this paper
• Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates

  2014cited by this paper
• Pick one, but be quick: 5' splice sites and the problems of too many choices.

  2013cited by this paper
• Splicing therapy for neuromuscular disease☆

  2013cited by this paper
• Exon skipping of hepatic APOB pre-mRNA with splice-switching oligonucleotides reduces LDL cholesterol in vivo.

  2013cited by this paper
• The 2014 version of the gene table of monogenic neuromuscular disorders (nuclear genome).

  2013cited by this paper
• Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study.

  2013cited by this paper
• Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness

  2013cited by this paper
• The missing puzzle piece: splicing mutations.

  2013cited by this paper
• Quantification of dystrophin immunofluorescence in dystrophinopathy muscle specimens

  2012cited by this paper
• Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs

  2012cited by this paper
• Overview of alternative oligonucleotide chemistries for exon skipping.

  2012cited by this paper
• Genetic Therapeutic Approaches for Duchenne Muscular Dystrophy

  2012cited by this paper
• Overview on applications of antisense-mediated exon skipping.

  2012cited by this paper
• Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges.

  2012cited by this paper
• Systemic administration of PRO051 in Duchenne's muscular dystrophy.

  2011cited by this paper
• Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy

  2011cited by this paper
• Clinical and genetic heterogeneity in laminopathies.

  2011cited by this paper
• Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

  2011cited by this paper
• Antitumorigenic potential of STAT3 alternative splicing modulation

  2011cited by this paper
• Splicing-Directed Therapy in a New Mouse Model of Human Accelerated Aging

  2011cited by this paper
• Antisense-mediated modulation of splicing: Therapeutic implications for Duchenne muscular dystrophy

  2010cited by this paper
• Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

  2010cited by this paper
• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• Cadherin-23, myosin VIIa and harmonin, encoded by Usher syndrome type I genes, form a ternary complex and interact with membrane phospholipids

  2010cited by this paper
• Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: implication for clinical trials.

  2010cited by this paper
• The development of antisense oligonucleotide therapies for Duchenne muscular dystrophy: report on a TREAT-NMD workshop hosted by the European Medicines Agency (EMA), on September 25th 2009.

  2010cited by this paper
• Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model.

  2010cited by this paper
• Immunohistological intensity measurements as a tool to assess sarcolemma‐associated protein expression

  2009cited by this paper
• RNA repair restores hemoglobin expression in IVS2–654 thalassemic mice

  2009cited by this paper
• Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

  2009cited by this paper
• Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice.

  2008cited by this paper
• Antisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB

  2007cited by this paper
• Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon

  2007cited by this paper
• Local dystrophin restoration with antisense oligonucleotide PRO051.

  2007cited by this paper
• Hutchinson–Gilford progeria syndrome: Review of the phenotype

  2006cited by this paper
• RNAi-mediated gene silencing in non-human primates

  2006cited by this paper
• Why Do Humans Have So Few Genes?

  2005cited by this paper
• Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome

  2005cited by this paper
• The nuclear lamina comes of age

  2005cited by this paper
• The USH1C 216G→A splice-site mutation results in a 35-base-pair deletion

  2005cited by this paper
• Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics

  2004cited by this paper
• Human tra2-beta1 autoregulates its protein concentration by influencing alternative splicing of its pre-mRNA.

  2004cited by this paper
• Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

  2004cited by this paper
• A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice

  2003cited by this paper
• Dystrophin and mutations: one gene, several proteins, multiple phenotypes.

  2003cited by this paper
• Genome-Wide Survey of Human Alternative Pre-mRNA Splicing with Exon Junction Microarrays

  2003cited by this paper
• Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome

  2003cited by this paper
• A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.

  2003cited by this paper
• Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA.

  2003cited by this paper
• Gene silencing in mammals by small interfering RNAs

  2002cited by this paper
• Myosin VIIa, harmonin and cadherin 23, three Usher I gene products that cooperate to shape the sensory hair cell bundle

  2002cited by this paper
• Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation.

  2002cited by this paper
• Directed evolution of proteins by exon shuffling

  2001cited by this paper
• Inhibition of zebrafish fgf8 pre‐mRNA splicing with morpholino oligos: A quantifiable method for gene knockdown

  2001cited by this paper
• A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2.

  1999cited by this paper
• Identification and characterization of a spinal muscular atrophy-determining gene

  1995cited by this paper
• Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.

  1993cited by this paper
• Unusual splice sites revealed by mutagenic inactivation of an authentic splice site of the rabbit β-globin gene

  1983cited by this paper
• β+ Thalassemia: Aberrant splicing results from a single point mutation in an intron

  1981cited by this paper

• Antisense Versus Antigene in the Computer-Aided Design of Triplex-Forming Oligonucleotides (TFO): Insights from a Dual-Method Review, Combining Bibliometric and Systematic Review

  2025cites this paper
• SIMPATHIC: Accelerating drug repurposing for rare diseases by exploiting SIMilarities in clinical and molecular PATHology.

  2025cites this paper
• Alternative Splicing as a Modulator of the Interferon-Gamma Pathway

  2025cites this paper
• The role of alternative splicing and splicing factors in diabetes: Current status and future perspectives

  2024cites this paper
• Covalent targeting of splicing in T cells.

  2024cites this paper
• The nexus of long noncoding RNAs, splicing factors, alternative splicing and their modulations

  2023cites this paper
• Evaluation of Chemically Modified Nucleic Acid Analogues for Splice Switching Application

  2023cites this paper
• New Zwitter-Ionic Oligonucleotides: Preparation and Complementary Binding

  2023cites this paper
• Chapter 2 Antisense RNA Therapeutics : A Brief Overview

  2022cites this paper
• Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides

  2022cites this paper
• Splicing Modulation as a Promising Therapeutic Strategy for Lysosomal Storage Disorders: The Mucopolysaccharidoses Example

  2022cites this paper
• Nucleic Acid Drugs—Current Status, Issues, and Expectations for Exosomes

  2021cites this paper
• Antisense Oligonucleotide-Mediated Splice Switching: Potential Therapeutic Approach for Cancer Mitigation

  2021cites this paper
• Delivery of oligonucleotide‐based therapeutics: challenges and opportunities

  2021cites this paper
• Macrophage development and activation involve coordinated intron retention in key inflammatory regulators

  2020cites this paper
• Modern approaches in gene therapy of motor neuron diseases

  2020cites this paper
• Disease-modifying therapies in amyotrophic lateral sclerosis.

  2020cites this paper
• RNA Metabolism and Therapeutics in Amyotrophic Lateral Sclerosis

  2019cites this paper
• Alternative Splicing of ALS Genes: Misregulation and Potential Therapies

  2019cites this paper
• COST Actions: fostering collaborative research for rare diseases.

  2019cites this paper
• Practical Aspects in Genetic Testing for Cardiomyopathies and Channelopathies.

  2019cites this paper
• Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics

  2018cites this paper
• Correction of a Splicing Mutation Affecting an Unverricht-Lundborg Disease Patient by Antisense Therapy

  2018cites this paper
• Design of peptide-based vector for nucleic acid delivery in vivo

  2018cites this paper
• Genetics of hypertrophic cardiomyopathy: A review of current state

  2018cites this paper
• Alternative Splicing as a Target for Cancer Treatment

  2018cites this paper
• Hypertrophic cardiomyopathy.

  2018cites this paper
• Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal Dystrophies.

  2018cites this paper
• [Genetic tests in hypertrophic cardiomyopathy: Benefits, limitations, and applications in clinical practice].

  2018cites this paper
• Miocardiopatía hipertrófica

  2018cites this paper
• Silencing of BCR/ABL Chimeric Gene in Human Chronic Myelogenous Leukemia Cell Line K562 by siRNA-Nuclear Export Signal Peptide Conjugates

  2017cites this paper
• Oligonucleotide therapies for disorders of the nervous system

  2017cites this paper
• Cilia - The sensory antennae in the eye.

  2017cites this paper
• Splice-switching antisense oligonucleotides as therapeutic drugs

  2016cites this paper
• Global Approaches to Alternative Splicing and Its Regulation—Recent Advances and Open Questions

  2016cites this paper
• Double-target Antisense U1snRNAs Correct Mis-splicing Due to c.639+861C>T and c.639+919G>A GLA Deep Intronic Mutations

  2016cites this paper
• Small Molecule Modulators of Micro RNA and Their Role in Cancer Therapy

  2016cites this paper
• Transcriptomics and Gene Regulation

  2016cites this paper
• Therapeutic correction of ApoER2 splicing in Alzheimer's disease mice using antisense oligonucleotides

  2016cites this paper
• An Integrative Genomic Study of Dupuytren's Disease

  2016cites this paper
• Isoform switching of steroid receptor co-activator-1 attenuates glucocorticoid-induced anxiogenic amygdala CRH expression

  2016cites this paper
• Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study

  2016cites this paper
• Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells.

  2016cites this paper
• Alternative splicing analysis for finding novel molecular signatures in renal carcinomas

  2015cites this paper
• Alternative Splicing Modification as a Treatment for Genetic Disorders

  2015cites this paper
• A Novel Lentiviral Vector Model to Investigate the Mechanism of Insertional Mutagenesis by Aberrant Splicing

  2015cites this paper
• Identification d'éléments régulateurs du gène CFTR et applications pour la mucoviscidose

  2015cites this paper